Skip Navigation

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by GATTORNO, M.
Right arrow Articles by PISTOIA, V.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by GATTORNO, M.
Right arrow Articles by PISTOIA, V.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 1995 British Society for Rheumatology

other

ANTIPHOSPHOLIPID ANTIBODIES IN PAEDIATRIC SYSTEMIC LUPUS ERYTHEMATOSUS, JUVENILE CHRONIC ARTHRITIS AND OVERLAP SYNDROMES: SLE PATIENTS WITH BOTH LUPUS ANTICOAGULANT AND HIGH-TITRE ANTICARDIOLIPIN ANTIBODIES ARE AT RISK FOR CLINICAL MANIFESTATIONS RELATED TO THE ANTIPHOSPHOLIPID SYNDROME

M. GATTORNO*,, A. BUONCOMPAGNI*, A. C. MOLINARI{dagger}, G. C. BARBANO{ddagger}, G. MORREALE§, F. STALLA, P. PICCO*, P. G. MORI{dagger} and V. PISTOIA

*Divisions of Paediatrics II, Scientific Institute G. Gaslini; the I Paediatric Clinic, University of Genoa and Scientific Institute G. Gaslini Genoa, Italy
{dagger}Divisions of Paediatrics IV, Scientific Institute G. Gaslini; the I Paediatric Clinic, University of Genoa and Scientific Institute G. Gaslini Genoa, Italy
{ddagger}Divisions of Nephrology, Scientific Institute G. Gaslini; the I Paediatric Clinic, University of Genoa and Scientific Institute G. Gaslini Genoa, Italy
§Divisions of Service of Muscle Diseases, Scientific Institute G. Gaslini; the I Paediatric Clinic, University of Genoa and Scientific Institute G. Gaslini Genoa, Italy
Laboratory of Oncology, Scientific Institute G. Gaslini; the I Paediatric Clinic, University of Genoa and Scientific Institute G. Gaslini Genoa, Italy

Correspondence to: Correspondence to: M. Gattorno, Division of Paediatrics II, Scientific Institute G. Gaslini, Largo G. Gaslini, 5, 16147 Genoa, Italy.

Antiphospholipid antibodies (APA) are often associated with severe clinical manifestations, especially in the setting of systemic lupus erythematosus (SLE). Here we have investigated the prevalence of anticardiolipin antibodies (aCL) and lupus anticoagulant (LA) in paediatric patients affected with SLE, JCA and overlap syndromes (OS) and correlated the presence of aCL and LA with clinical features. aCL were assayed by enzyme-limited immunoassay; LA was determined by activated partial thromboplastin time and the kaolin clotting time test. aCL and LA assays were performed in parallel on at least two occasions over a 7–30-month follow-up. Fifteen out of nineteen (79%) SLE patients had aCL and 8/19 (42%) had LA. Six SLE patients displayed manifestations that were APA-related: deep venous thromboses, autoimmune haemolytic anaemia, pulmonary hypertension, neurological alterations. Five out of six symptomatic patients had both LA and high-titre aCL. In contrast, JCA and OS patients had usually low-titre aCL, no detectable LA and no APA-related manifestations. aCL persisted at high titre over time in SLE patients, but was only transiently detected in JCA and OS patients. This study shows that the simultaneous positivity for LA and high-titre aCL allows the identification of paediatric SLE patients who are at risk not only for thrombosis, but also for other APA-related clinical features.

KEY WORDS: Anticardiolipin antibodies, Lupus anticoagulant, Childhood systemic lupus erythematosus, Juvenile chronic arthritis, Overlap syndromes


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Rheumatology (Oxford)Home page
E. Descloux, I. Durieu, P. Cochat, D. Vital Durand, J. Ninet, N. Fabien, and R. Cimaz
Paediatric systemic lupus erythematosus: prognostic impact of antiphospholipid antibodies
Rheumatology, February 1, 2008; 47(2): 183 - 187.
[Abstract] [Full Text] [PDF]

Home page
 LupusHome page
I. Kone-Paut, M. Piram, S. Guillaume, and T.A. Tran
Review: Lupus in adolescence
Lupus, August 1, 2007; 16(8): 606 - 612.
[Abstract] [PDF]

Home page
 LupusHome page
T. Avcin and E. Silverman
Review: Antiphospholipid antibodies in pediatric systemic lupus erythematosus and the antiphospholipid syndrome
Lupus, August 1, 2007; 16(8): 627 - 633.
[Abstract] [PDF]

Home page
 LupusHome page
M Gattorno, F Falcini, A Ravelli, F Zulian, A Buoncompagni, G Martini, M Resti, P Picco, and A Martini
Outcome of primary antiphospholipid syndrome in childhood
Lupus, June 1, 2003; 12(6): 449 - 453.
[Abstract] [PDF]

Home page
 LupusHome page
T Avcin, R Cimaz, and P L Meroni
Recent advances in antiphospholipid antibodies and antiphospholipid syndromes in pediatric populations
Lupus, January 1, 2002; 11(1): 4 - 10.
[Abstract] [PDF]

Home page
 Rheumatology (Oxford)Home page
T. Avcin, A. Ambrozic, M. Kuhar, T. Kveder, and B. Rozman
Anticardiolipin and anti-{beta}2 glycoprotein I antibodies in sera of 61 apparently healthy children at regular preventive visits
Rheumatology, May 1, 2001; 40(5): 565 - 573.
[Abstract] [Full Text] [PDF]

Home page
 LupusHome page
A. Andrews and P. Hickling
Thrombosis associated with antiphospholipid antibody in juvenile chronic arthritis
Lupus, January 1, 1997; 6(6): 556 - 557.
[Abstract] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.